Omeros Corp(OMER) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 12.93 | EPS (ttm) | 1.44 | Insider Own | 4.29% | Shs Outstand | 72.1M | Perf Week | -1.43% |
| Market Cap | 1.35B | Forward P/E | 18.59 | EPS next Y | 12.36% | Insider Trans | -3.22% | Shs Float | 69.3M | Perf Month | 36.69% |
| Enterprise Value | 1.51B | PEG | - | EPS next Q | 0.02 | Inst Own | 51.2% | Short Float | 21.13% | Perf Quarter | 82.25% |
| Income | 0.12B | P/S | 35.03 | EPS this Y | 1880% | Inst Trans | 8.48% | Short Ratio | 7.14 | Perf Half Y | 55.83% |
| Sales | 0.04B | P/B | - | EPS next 5Y | - | ROA | 47.82% | Short Interest | 14.64M | Perf YTD | 8.24% |
| Book/sh | -0.71 | P/C | 10.2 | EPS past 3/5Y | - 53.45% | ROE | - | 52W High | -5.39% ($19.65) | Perf Year | 335.36% |
| Cash/sh | 1.82 | P/FCF | - | Sales past 3/5Y | - | ROIC | 67.05% | 52W Low | 371.83% ($3.94) | Perf 3Y | 451.63% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 181.47% | Gross Margin | 94.02% | Volatility(W/M) | 3.55% 4.94% | Perf 5Y | 18.94% |
| Dividend TTM | - | EV/Sales | 39.32 | Sales Y/Y TTM | - | Oper. Margin | -189.53% | ATR (14) | 0.87 | Perf 10Y | 69.93% |
| Dividend Ex-Date | - | Quick Ratio | 1.94 | EPS Q/Q | 134.01% | Profit Margin | 324.88% | RSI (14) | 62.76 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.95 | Sales Q/Q | - | SMA20 | 0.05% ($18.58) | Beta | 2.57 | Target Price | $44 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/12 | SMA50 | 32% ($14.08) | Rel Volume | 0.6 | Prev Close | $19.39 |
| Employees | 175 | LT Debt/Eq | - | EPS/Sales Surpr. | 155.91% 124.79% | SMA200 | 51.13% ($12.3) | Avg Volume(3M) | 2.05M | Price | $18.59 |
| IPO | 2009/10/8 | Option/Short | Yes/Yes | Trades | 11628 | Volume | 1,231,803 | Change | -4.13% |
Company
OMER is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Omeros (OMER) is an innovative biopharmaceutical company targeting immune and complement-mediated diseases. Centered on a drug platform that inhibits MASP-2, a key enzyme in the lectin pathway, it focuses on developing and commercializing a pipeline of small-molecule and protein therapeutics aimed at both rare diseases and large indications.
Over the past 1 year, on the higher side
5% below its 1-year high.
OMER has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1880.0% this year.
Tap to view numbers
The stock looks undervalued
Trading at 12.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +451.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 51.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PILL 0.02%
XPH 0.01%
BBC 0.01%
FOXY 0.00%
SBAR 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
ACSI 117M
WNDR -
STYL -It ranks #4 in the industry
Based on market cap of $1B.
OMER $1B PER 12.9
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is OMER?
OMER belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OMER?
The market cap of OMER is approximately $1.3B, ranking 2,416 within its sector.
What is the P/E ratio of OMER?
OMER has a P/E ratio of approximately 12.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OMER?
OMER has recorded a 52-week high of $19.65 and a low of $3.94.
